interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Escitalopram Oxalate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Escitalopram Oxalate, and who makes it?

Escitalopram Oxalate appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 14 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 9.3 and 9.6 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Escitalopram Oxalate3 dosage-form groups in the Orange Book
14generic makers listed
  1. Escitalopram Oxalate appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 14 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 9.3 and 9.6 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Lexapro. 12 generic makers with 36 generic products listed as marketed; the first generic approval is dated 14 March 2012.

2000200520102015202020252030012brand 2002Accord Healthcare Inc, first approval 11 September 2012Aurobindo Pharma Ltd, first approval 11 September 2012Chartwell Rx Sciences Llc, first approval 11 September 2012Graviti Pharmaceuticals Private Ltd, first approval 11 September 2012Invagen Pharmaceuticals Inc, first approval 11 September 2012Macleods Pharmaceuticals Ltd, first approval 11 September 2012Torrent Pharmaceuticals Ltd, first approval 11 September 2012Zydus Lifesciences Ltd, first approval 11 September 2012Jubilant Cadista Pharmaceuticals Inc, first approval 12 September 2012Prinston Pharmaceutical Inc, first approval 28 August 2015Amneal Pharmaceuticals, first approval 17 May 2017Ascent Pharmaceuticals Inc, first approval 15 July 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Accord Healthcare Inc11 September 20123
Aurobindo Pharma Ltd11 September 20123
Chartwell Rx Sciences Llc11 September 20123
Graviti Pharmaceuticals Private Ltd11 September 20123
Invagen Pharmaceuticals Inc11 September 20123
Macleods Pharmaceuticals Ltd11 September 20123
Torrent Pharmaceuticals Ltd11 September 20123
Zydus Lifesciences Ltd11 September 20123
Jubilant Cadista Pharmaceuticals Inc12 September 20123
Prinston Pharmaceutical Inc28 August 20153
Amneal Pharmaceuticals17 May 20173
Ascent Pharmaceuticals Inc15 July 20253

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Oral

Four or more generic makers listed

Every brand product here is listed as discontinued. 5 generic makers with 5 generic products listed as marketed; the first generic approval is dated 14 March 2012.

200020052010201520202025203005brand 2002Amneal Pharmaceuticals, first approval 14 March 2012Aurobindo Pharma Ltd, first approval 2 April 2012Hetero Labs Ltd Unit Iii, first approval 12 June 2012Chartwell Molecular Holdings Llc, first approval 12 June 2013Macleods Pharmaceuticals Ltd, first approval 31 March 2016data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Amneal Pharmaceuticals14 March 20121
Aurobindo Pharma Ltd2 April 20121
Hetero Labs Ltd Unit Iii12 June 20121
Chartwell Molecular Holdings Llc12 June 20131
Macleods Pharmaceuticals Ltd31 March 20161

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Escitalopram. No generic is listed as marketed (3 generic products listed as discontinued).

20202025203001brand 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.